Epigenetic modification of the TNF promoter is associated with rheumatoid arthritis

被引：0
|
作者：
Gowers, I. R. [1 ]
Duff, G. W. [1 ]
Wilson, A. G. [1 ]
机构：
[1] Univ Sheffield, Sch Med & Biomed Sci, Sheffield, S Yorkshire, England
来源：
RHEUMATOLOGY | 2007年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：I19 / I20
页数：2
相关论文
共 50 条
  • [31] Epigenetic contributions in the development of rheumatoid arthritis
    Klein, Kerstin
    Ospelt, Caroline
    Gay, Steffen
    ARTHRITIS RESEARCH & THERAPY, 2012, 14 (06)
  • [32] Epigenetic Regulation in the Pathogenesis of Rheumatoid Arthritis
    Yang, Chao
    Li, Dan
    Teng, Dehong
    Zhou, Yueru
    Zhang, Lei
    Zhong, Zhangfeng
    Yang, Guan-Jun
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [33] Polymorphism in the TNF promoter gene (-308A) correlates with worse response to infliximab in rheumatoid arthritis
    Pinto, JA
    Mosquera, A
    Fernandez-García, JL
    Freire, M
    De Toro, FJ
    Maneiro, E
    Lopez-Armada, MJ
    Galdo, F
    Blanco-García, F
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 305 - 305
  • [34] The Pivotal Role of TNF -α in Rheumatoid Arthritis
    Kodar Lee
    中华中医药学刊, 2004, (10) : 1847 - 1849
  • [35] TNF as a Target of Inflammation in Rheumatoid Arthritis
    Yamanaka, Hisashi
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2015, 15 (02) : 129 - 134
  • [36] TNFα inhibitors for the treatment of rheumatoid arthritis
    Sany, J
    Kaiser, MJ
    ANNALES DE MEDECINE INTERNE, 2002, 153 (01): : 34 - 40
  • [37] TNF inhibition as therapy for rheumatoid arthritis
    Wollheim, FA
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (07) : 947 - 953
  • [38] Lymphoma, rheumatoid arthritis, and TNFα antagonists
    Mariette, Xavier
    JOINT BONE SPINE, 2010, 77 (03) : 195 - 197
  • [39] The introduction of TNF blockade in rheumatoid arthritis
    Maini, RN
    Feldmann, M
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 13 - 13
  • [40] TNF-α inhibitors and rheumatoid arthritis
    Shire, MG
    Muller, GW
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (05) : 531 - 544
12345